Table 3

Microarray study characteristics
Study	Institution	Outcome	Microarray platform	Evaluated genes	Number of samples^a	Total time at risk, years	Median time at risk, years	Number deaths/recurrences

Blenkiron, et al. [22]	Nottingham City Hospital (Nottingham, UK)	All-cause mortality	Illumina (San Diego, CA, USA)	PGC, FRS3, C6orf49, TRFP, BYSL, USP49, CCND3	128	1,198.0	11.1	45
Chin, et al. [23]	University of California at San Francisco	All-cause mortality	Affymetrix U133A (Santa Clara, CA, USA)	PGC, FRS3, C6orf49, TRFP, BYSL, CCND3	129	822.6	6.0	45
Miller, et al. [24]	Uppsala, Sweden	All-cause mortality	Affymetrix U133A	PGC, FRS3, C6orf49, BYSL, CCND3	234	1,927.5	10.2	54
Sørlie, et al. [25]	Stanford University (Stanford, CA, USA)	All-cause mortality	cDNA	BYSL, USP49, CCND3	76	227.6	2.5	30
Sotiriou, et al. [26]	John Radcliffe (Oxford, UK)	Disease recurrence	Affymetrix U133A	PGC, FRS3, TRFP, BYSL, CCND3	94	709.9	7.3	24^b
van de Vijver, et al. [27]	The Netherlands Cancer Institute (Amsterdam)	All-cause mortality	Agilent Technologies, Inc. (Santa Clara, CA, USA)	PGC, FRS3, C6orf49, BYSL, USP49, CCND3	295	2,319.8	7.2	79
Wang, et al. [28]	Erasmus (Rotterdam, The Netherlands)	Disease recurrence	Affymetrix U133A	PGC, C6orf49, FRS3, USP49, BYSL, CCND3	285	1,843.1	7.2	107^b
Total					1,241	9,048.4	7.4	384

^aWith endpoint data. ^bDisease recurrence.
Azzato et al. Breast Cancer Research 2008 10:R47 doi:10.1186/bcr2100